Drug Safety

, Volume 29, Issue 3, pp 189–199

A Preliminary Benefit-Risk Assessment of Verteporfin in Age-Related Macular Degeneration

Review Article

Abstract

The prevalence of neovascular age-related macular degeneration (AMD) is expected to increase significantly during the next 20 years. New treatment alternatives to laser photocoagulation are on the horizon — the first of these, photodynamic therapy (PDT) with verteporfin, was approved by the US FDA in 2000. In this article we present a preliminary risk-benefit assessment of verteporfin in AMD, focusing on the landmark randomised, double-blind, placebo-controlled studies. The TAP (Treatment of Age-related macular degeneration with Photodynamic therapy) trial established the efficacy of PDT for classic subfoveal neovascularisation in AMD at 2 years follow-up. The VIP (Verteporfin in Photodynamic therapy) study concentrated on subfoveal occult-only lesions not included in the TAP study. After 2 years, treated eyes were less likely to experience visual loss. Exploratory analyses of TAP and VIP suggest that lesion size is a more significant predictor of the treatment benefit than either lesion composition or visual activity. The VIM (Visudyne® in Minimally classic) trial altered the standard PDT light fluence rate in the treatment of subfoveal minimally classic lesions. This trial again demonstrated a beneficial effect for those receiving treatment with PDT. The VIO (Visudyne® in Occult) trial, evaluating PDT in occult-only lesions as a confirmatory study of the VIP trial, did not achieve its primary end-point at 2 years. Further analyses are pending.

PDT with verteporfin has an excellent safety profile that has been established with >1 million treatment applications. Cost-effectiveness data are limited but suggest that PDT may be a cost-effective treatment modality. Other FDA-approved treatments (pegaptanib, ranibizumab and bevacizumab) for neovascular AMD are discussed, as well as investigational substances such as anecortave acetate.

References

  1. 1.
    Bressler NM, Bressler SB, Fine SL. Age-related macular degeneration. Surv Ophthalmol 1988; 32(6): 375–413PubMedCrossRefGoogle Scholar
  2. 2.
    Ferris III FL, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol 1984; 102: 1640–2PubMedCrossRefGoogle Scholar
  3. 3.
    Bressler NM, Bressler SB, Congdon NG, et al. Potential public health impact of age-related eye disease study results: AREDS report no. 11. Arch Ophthalmol 2003; 121: 1621–4PubMedCrossRefGoogle Scholar
  4. 4.
    Subfoveal neovascular lesions in age-related macular degeneration: guidelines for evaluation and treatment in the macular photocoagulation study. Macular Photocoagulation Study Group. Arch Ophthalmol 1991; 109: 1242–57Google Scholar
  5. 5.
    Bressler NM, Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2. Arch Ophthalmol 2001; 119: 198–207PubMedGoogle Scholar
  6. 6.
    Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal neovascular lesions of age-related macular degeneration: updated findings from two clinical trials. Arch Ophthalmol 1993; 111: 1200–9Google Scholar
  7. 7.
    Verteporfin in Photodynamic Therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization: verteporfin in photodynamic therapy report 2. Am J Ophthalmol 2001; 131: 541–60Google Scholar
  8. 8.
    Macular Photocoagulation Study Group. Subfoveal neovascular lesions in age-related macular degeneration: guidelines for evaluation and treatment in the macular photocoagulation study. Arch Ophthalmol 1991; 109: 1242–57Google Scholar
  9. 9.
    Schmidt-Erfurth U, Hasan T. Mechanisms of action of photodynamic therapy with verteporfin for the treatment of age-related macular degeneration. Surv Ophthalmol 2000; 45(3): 195–214PubMedCrossRefGoogle Scholar
  10. 10.
    Scott LJ, Goa KL. Verteporfin. Drugs Aging 2000; 16: 139–46PubMedCrossRefGoogle Scholar
  11. 11.
    Houle JM, Strong A. Clinical pharmacokinetics of verteporfin. J Clin Pharmacol 2002; 42: 547–57PubMedCrossRefGoogle Scholar
  12. 12.
    Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials — TAP report. Treatment of Age-related macular degeneration with Photodynamic therapy (TAP) Study Group. Arch Ophthalmol 1999; 117: 1329–45Google Scholar
  13. 13.
    Azab M, Boyer DS, Bressler NM, Visudyne in Minimally Classic Choroidal Neovascularization Study Group. Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial. Arch Ophthalmol 2005; 123: 448–57PubMedCrossRefGoogle Scholar
  14. 14.
    QLT Inc. QLT announces two year results of Visudyne® in occult (VIO) trial. Media release, 2005 Sep 20 [online]. Available from URL: http://www.qltinc.com [Accessed 2006 Jan 5]Google Scholar
  15. 15.
    Japanese age-related macular degeneration trial: 1-year results of photodynamic therapy with verteporfin in Japanese patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Am J Ophthalmol 2003; 136: 1049–61Google Scholar
  16. 16.
    Bressler NM. Verteporfin therapy in age-related macular degeneration (VAM): an open-label multicenter photodynamic therapy study of 4,435 patients. Retina 2004; 24: 512–20CrossRefGoogle Scholar
  17. 17.
    Blumenkranz MS, Bressler NM, Bressler SB, et al. Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: three-year results of an open-label extension of 2 randomized clinical trials: TAP report no. 5. Arch Ophthalmol 2002; 120: 1307–14PubMedGoogle Scholar
  18. 18.
    Bressler NM. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization-verteporfin in photodynamic therapy report 2. Am J Ophthalmol 2002; 133: 168–9PubMedCrossRefGoogle Scholar
  19. 19.
    Blinder KJ, Bradley S, Bressler NM, et al. Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report no. 1. Am J Ophthalmol 2003; 136: 407–18PubMedCrossRefGoogle Scholar
  20. 20.
    Rubin GS, Bressler NM. Effects of verteporfin therapy on contrast on sensitivity: results from the treatment of age-related macular degeneration with photodynamic therapy (TAP) investigation-TAP report no 4. Retina 2002; 22: 536–44PubMedCrossRefGoogle Scholar
  21. 21.
    Azab M, Benchaboune M, Blinder KJ, et al. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: meta-analysis of 2-year safety results in three randomized clinical trials: treatment of age-related macular degeneration with photodynamic therapy and verteporfin in photodynamic therapy study report no. 4. Retina 2004; 24: 1–12PubMedCrossRefGoogle Scholar
  22. 22.
    Arnold JJ, Blinder KJ, Bressler NM, et al. Acute severe visual acuity decrease after photodynamic therapy with verteporfin: case reports from randomized clinical trials-TAP and VIP report no. 3. Am J Ophthalmol 2004; 137: 683–96PubMedCrossRefGoogle Scholar
  23. 23.
    Verteporfin Roundtable Participants. Guidelines for using verteporfin (Visudyne) in photodynamic therapy for choroidal neovascularization due to age-related macular degeneration and other causes: update. Retina 2005; 25: 119–34Google Scholar
  24. 24.
    Schmidt-Erfurth U, Schlotzer-Schrehard U, Cursiefen C, et al. Influence of photodynamic therapy on expresson of vascular endothelial growth factor (VEGF), VEGF receptor 3, and pigment epithelium-derived factor. Invest Ophthalmol Vis Sci 2003; 44: 4473–80PubMedCrossRefGoogle Scholar
  25. 25.
    Ishibashi T, Miki K, Sorgente N, et al. Effects of intravitreal administration of steroids on experimental subretinal neovascularization in the subhuman primate. Arch Ophthalmol 1985; 103: 708–11PubMedCrossRefGoogle Scholar
  26. 26.
    Antoszyk AN, Gottlieb JL, Machemer R, et al. The effects of intravitreal triamcinolone acetonide on experimental pre-retinal neovascularization. Grafes Arch Clin Exp Ophthalmol 1993; 231: 34–40CrossRefGoogle Scholar
  27. 27.
    Danis RP, Bingaman DP, Yang Y, et al. Inhibition of preretinal and optic nerve head neovascularization in pigs by intravitreal triamcinolone acetonide. Ophthalmology 1996; 103: 2099–104PubMedGoogle Scholar
  28. 28.
    Ciulla TA, Criswell MH, Danis RP, et al. Intravitreal triamcinolone acetonide inhibits choroidal neovascularization in a laser-treated rat model. Arch Ophthalmol 2001; 119: 399–404PubMedGoogle Scholar
  29. 29.
    Danis RP, Ciulla TA, Pratt LM, et al. Intravitreal triamcinolone acetonide in exudative age-related macular degeneration. Retina 2000; 20: 244–50PubMedCrossRefGoogle Scholar
  30. 30.
    Gillies MC, Simptson JM, Luo W, et al. A randomized clinical trial of a single dose of intravitreal triamcinolone acetonide for neovascular age-related macular degeneration: one year results. Arch Ophthalmol 2003; 121: 667–73PubMedCrossRefGoogle Scholar
  31. 31.
    Spaide RF, Sorenson J, Maranan L. Photodynamic therapy with verteporfin combined with intravitreal injection of triamcinolone acetonide for choroidal neovascularization. Ophthalmology 2005; 112: 301–4PubMedCrossRefGoogle Scholar
  32. 32.
    Rechtman E, Danis RP, Pratt LM, et al. Intravitreal triamcinolone with photodynamic therapy for subfoveal choroidal neovascularization in age related macular degeneration. Br J Ophthalmol 2004; 88: 344–7PubMedCrossRefGoogle Scholar
  33. 33.
    Smith DH, Fenn P, Drummond M. Cost effectiveness of photodynamic therapy with verteporfin for age-related macular degeneration: the UK case. Br J Ophthalmol 2004; 88: 1107–12PubMedCrossRefGoogle Scholar
  34. 34.
    Sharma S, Brown GC, Brown MM, et al. The cost-effectiveness of photodynamic therapy for fellow eyes with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology 2001; 108: 2051–9PubMedCrossRefGoogle Scholar
  35. 35.
    Brown GC, Brown MM, Campanella J, et al. The cost-utility of photodynamic therapy in eyes with neovascular macular degeneration: a value-based reappraisal with 5-year data. Am J Ophthalmol 2005; 140: 679–87PubMedGoogle Scholar
  36. 36.
    Gragoudas ES, Adamis AP, Cunningham Jr ET, et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004; 351: 2805–16PubMedCrossRefGoogle Scholar
  37. 37.
    New data from two leading clinical studies show Lucentis® is first therapy to improve vision in wet age-related macular degeneration (AMD) [online]. Available from URL: http://dominoext.novartis.com [Accessed 2006 Jan 11]Google Scholar
  38. 38.
    Preliminary data from phase III trial show lucentis is the first investigational therapy to demonstrate clinical benefit over visudyne in a head-to-head study of patients with wet AMD [online]. Available from URL: http://www.gene.com [Accessed 2006 Feb 8]Google Scholar
  39. 39.
    Michels S, Rosenfeld PJ, Puliafito CA, et al. Systemic bevacizumab (avastin) therapy for neovascular age-related macular degeneration: twelve-week results of an uncontrolled open-label clinical study. Ophthalmology 2005; 112: 1035–47PubMedCrossRefGoogle Scholar
  40. 40.
    Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Case reports: optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. Ophthalmic Surg, Lasers Imaging 2005; 36: 331–5Google Scholar
  41. 41.
    Clark AF. AL-3789; a novel ophthalmic angiostatic steroid. Expert Opin Investig Drugs 1997; 6: 2867–77Google Scholar
  42. 42.
    The Anecortave Acetate Clinical Study Group: Anecortave acetate as monotherapy for treatment of subfoveal neovascularization in age-related macular degeneration twelve-month clinical outcomes. Ophthalmology 2003; 110: 2372–85Google Scholar
  43. 43.
    Hawkins BS, Bressler NM, Miskala PH, et al. Surgery for subfoveal choroidal neovascularization in age-related macular degeneration: ophthalmic findings: SST report no. 11. Ophthalmology 2004; 111: 1967–80PubMedCrossRefGoogle Scholar
  44. 44.
    Reichel E. Transpupillary thermotherapy. In: Retina 2004: everything you ever wanted to know about retina [Subspecialty Day at the American Academy of Ophthalmology Annual Meeting]; 2004 Oct 22-23; New Orleans (LA): American Academy of Ophthalmology, 2004 [CD-ROM]Google Scholar

Copyright information

© Adis Data Information BV 2006

Authors and Affiliations

  1. 1.Barnes Retina Institute, Department of OphthalmologyWashington University School of MedicineSt LouisUSA

Personalised recommendations